Development Capability|

We are committed to developing biologics with other biopharmaceutical companies or research institutions which have tremendous market potentials and show good effect in former researches. It skips the early research stage and jump right into process development, pre-clinical and clinical stage, which minimizes the cycle time of development process and reduce the risks, thus access to higher success rates. During the process, we will achieve intellectual property rights and declare patent, thus help to ensure its role as a leader in technology platform, innovation and intellectual property rights. Now we have made headway in building up a portfolio of 11 molecules targeted towards indications in breast cancer, lymphoma, autoimmune disorders, and NSCLC etc.